The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISTH 2022 | Long-term safety & efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia
Mehran Karimi, MD, Hematology Research Center Shiraz University of Medical Sciences, Shiraz, Iran, comments on the use and long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia, highlighting the mechanism of action of this drug. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.
